JPM26: 2025 a “breakout year” for rare disease biotechs [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
Several rare disease biotechs hailed commercial successes in 2025 as marking a turning point in the sector's maturation, despite lingering reliance on single lead assets and pressure to cut staff to remain financially stable. Even so, developers promised deepening pipelines and regulatory advancement in 2026 to attendees at the 2026 J.P. Morgan Healthcare conference in San Francisco, taking place from 12 to 15 January. 2025 was a “breakout year” for siRNA biotech Alnylam Pharmaceuticals according to CEO Yvonne Greenstreet. The company secured FDA approval for its flagship asset Amvuttra (vutrisiran) in transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) in March and achieved nearly $3bn in combined sales throughout the year. Greenstreet said Alnylam now projects sales as high as $5.3bn in 2026, noting as much as $4.7bn is expected to come solely from ATTR sales of Amvuttra and Onpattro (patisiran). During this year, she added the company expects four clinical readout
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal [Yahoo! Finance]Yahoo! Finance
- Adimab Reports Strong Partnering Year for 2025 [Yahoo! Finance]Yahoo! Finance
- Alnylam Pharmaceuticals Unveils “Alnylam 2030” as Amvuttra Drives Breakout Growth at JPMorgan Conf. [Yahoo! Finance]Yahoo! Finance
- Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Bank of America Corporation from $530.00 to $529.00. They now have a "buy" rating on the stock.MarketBeat
- Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Needham & Company LLC from $520.00 to $529.00. They now have a "buy" rating on the stock.MarketBeat
ALNY
Earnings
- 10/30/25 - Beat
ALNY
Sec Filings
- 1/14/26 - Form 4
- 1/14/26 - Form 4
- 1/14/26 - Form 4
- ALNY's page on the SEC website